<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04376216</url>
  </required_header>
  <id_info>
    <org_study_id>FHM-1-2017</org_study_id>
    <nct_id>NCT04376216</nct_id>
  </id_info>
  <brief_title>Prednisolone Treatment in Acute Interstitial Nephritis</brief_title>
  <acronym>PRAISE</acronym>
  <official_title>Prednisolon Behandling Ved Akut Interstitiel Nefritis - et Randomiseret, Prospektivt Studie</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region MidtJylland Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Region MidtJylland Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Prospective randomized trial with a primary objective to investigate the effect&#xD;
      ofprdenisolone treatment in acute interstitial nephritis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2026</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>eGFR</measure>
    <time_frame>3 months</time_frame>
    <description>Kidney function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>eGFR</measure>
    <time_frame>12 months</time_frame>
    <description>Kidney function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary biomarkers</measure>
    <time_frame>at inclusion and after3 and 12 months</time_frame>
    <description>NGAL, NAG, KIM-1, TIMP-2, IGFBP7, IL-6, IL-18 and MCP-1 are the biomarkers that the investigators plan to analyze</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathology</measure>
    <time_frame>At inclusion</time_frame>
    <description>Re-evaluation of renal biospies performed at time of inclusion. This evaluation includes the use of routine and special staining for inflammation, fibrosis and tubular damage. The analysis includes an estimation of predictive value of histological scoring on treatment response and prognosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for renal replacement therapy</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Dialysis need</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose or hemoglobin A1C</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Development of diabetes (safety)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment delay</measure>
    <time_frame>At inclusion</time_frame>
    <description>In the prednisolone group the importance of &quot;treatment delay&quot; is analyzed. Treatment delay is defined as follows:&#xD;
Days form first symptoms to inclusion in this project&#xD;
Days from first contact to the Danish health care system to inclusion in this project&#xD;
Days from first contact to a nephrology department to inclusion in this project</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections (number of events)</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admissions (number of events)</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Acute Tubulo-Interstitial Nephritis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral prednisone. Starting dose of 60 mg with tapering for 2 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>60 mg with dose tapering over 2 months</description>
    <arm_group_label>Prednisone</arm_group_label>
    <other_name>Prednisolone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy verified AIN&#xD;
&#xD;
          -  Clinical suspicion of AIN&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  One of following criteria:&#xD;
&#xD;
               -  Plasma creatinine &gt; 120 µmol/L or&#xD;
&#xD;
               -  Plasma creatinine increase &gt; 30 µmol/L or increase &gt; 50 % of baseline plasma&#xD;
                  creatinine&#xD;
&#xD;
          -  Fertile women are included&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No ability to give informed consent&#xD;
&#xD;
          -  Immunosuppressive treatment (including prednisolone) within 3 months before biopsy&#xD;
&#xD;
          -  Autoimmune disease&#xD;
&#xD;
          -  Prednisolone intolerance&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Active cancer (except basal cell carcinoma)&#xD;
&#xD;
          -  Short life expectancy (&lt; 6 months)&#xD;
&#xD;
          -  CKD stage IV-V&#xD;
&#xD;
          -  AIN secondary to or accompanied by glomerulonephritis, sarcoidosis or inherited&#xD;
             interstitial renal disease&#xD;
&#xD;
          -  Previous participation Withdrawal criteria&#xD;
&#xD;
          -  Development of exclusion criterion&#xD;
&#xD;
          -  Withdrawal of consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesper N Bech, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Region MidtJylland Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frank Mose, MD</last_name>
    <phone>+4528531257</phone>
    <email>frchri@rm.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Godstrup Hospital</name>
      <address>
        <city>Herning</city>
        <zip>7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Mose</last_name>
      <phone>28531257</phone>
      <email>frchri@rm.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>May 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>December 29, 2020</last_update_submitted>
  <last_update_submitted_qc>December 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Region MidtJylland Denmark</investigator_affiliation>
    <investigator_full_name>Frank Mose</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Acute Tubulo-Interstitial Nephritis</keyword>
  <keyword>Prednisone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Nephritis, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Will be decided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

